CRISPR-Cas9 approaches to model blood cancers in vivo.

This project involves the use of gene editing of primary mouse and human bone marrow cells and monitoring disease phenotypes. We will use Cas9 editing on adult stem cell populations derived from bone marrow to introduce oncogenic mutations that are found from patients with leukaemia. These cells can be propagated in vitro or in vivo and will be used to assess the impact of genetic mutations on disease development and/or treatment response.

For more information on this research group: http://www.qimrberghofer.edu.au/lab/gordon-and-jessie-gilmour-leukaemia-research/